Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...

The Indian phenotype of T2DM patients is associated with clustering of cardiovascular risk factors, increased insulin ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

For example, clinicians can incorporate treatments that target chronic inflammation, oxidative stress, and hormonal pathways into their strategies for managing patients with endometriosis.

Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue NUBEQA for ... which prioritizes targets and pathways with the potential to impact the ...

Li, Y. and Zhou, B. (2025) Research Progress on the Relationship between Dynapenic Obesity and Type 2 Diabetes. Journal of Biosciences and Medicines, 13, 256-267. doi: 10.4236/jbm.2025.132020 .

Furthermore, relevant secondary targets and associated pathways were investigated to substantiate ... In this study, we have identified an association between dyslipidemia and Type II EC. Genetically ...

AACE published its first updated guideline on the pharmacologic management of adults with dyslipidemia since 2017. New recommendations include medications that have been approved since the last ...